ALKS - Alkermes plc
| Previous Close | 20.93 |
| Open | 20.92 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 3200 |
| Day's Range | 20.81 - 21.38 |
| 52 Week Range | 17.11 - 37.75 |
| Volume | 995,158 |
| Avg. Volume | 1,587,215 |
| Market Cap | 3.3B |
| Beta (5Y Monthly) | 1.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.28 |
| Earnings Date | Feb 12, 2020 - Feb 17, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.73 |
- Zacks
Amgen's Osteoporosis Drug Evenity Gets Approval in Europe
The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
- Zacks
Proteostasis Therapeutics (PTI) in Focus: Stock Moves 7.3% Higher
Proteostasis Therapeutics (PTI) shares rose more than 7% in the last trading session, amid huge volumes.
- MarketWatch
FDA told Alkermes to stop publishing Vivitrol ad
Shares of Alkermes were down 2.74% after the Food and Drug Administration published a warning letter alleging Vivitrol ads didn't include important risk information. If Vivitrol, which is used to prevent relapses in opioid addiction and is the drugmaker's top-selling drug, is used in conjunction with a previously tolerated dose of opioids, it can lead to an overdose. That information was not included in a print ad marketing the drug to the criminal justice system. The FDA told Alkermes to stop publishing the ad and to submit a response to the regulatory agency by Dec. 16. "The criminal justice system is an important aspect for us as people are more and more focused obviously on drug offenses and as opposed to violent offenses, how people can get treatment behind the walls. The prison system in the United States is not set up to deliver treatment," CFO James Frates told investors in July, according to a FactSet transcript of a Q2 earnings call. Vivitrol brought in $85.1 million in sales in the third quarter of 2019, up from $79.9 million in the same period in 2018. Alkermes' stock has dropped 29% year-to-date. The S&P 500 is up about 25%.
- Reuters
UPDATE 1-FDA issues warning letter to Alkermes over opioid addiction treatment ad
A print advertisement of Alkermes Plc's addiction treatment, Vivitrol, is false or misleading as it omits important risk information associated with its use, the Food and Drug Administration said in a warning letter http://bit.ly/2LGVKUM to the company. Users of Vivitrol as a treatment for opioid dependence should be made aware of the vulnerability to potentially fatal overdose at the end of a dosing interval, after missing a dose, or after discontinuing the treatment, the agency said in the letter dated Dec. 2. Vivitrol, used to prevent a relapse to opioid dependence following detoxification and to treat alcohol dependence, is one of Alkermes' top-selling drugs and brought in $85.2 million in the latest reported quarter.
- Zacks
TG Therapeutics' Shares Soar on Positive Early-Stage Data
TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.
- Zacks
Regeneron Reports Initial Data for Multiple Myeloma Drug
Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.
- Zacks
bluebird Reports Positive Top-Line Data on Myeloma Drug
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
- Simply Wall St.
Should You Be Pleased About The CEO Pay At Alkermes plc's (NASDAQ:ALKS)
Richard Pops has been the CEO of Alkermes plc (NASDAQ:ALKS) since 2011. This analysis aims first to contrast CEO...
- Zacks
Sage Therapeutics' Depression Drug Fails in Study, Stock Down
Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.
- Insider Monkey
Hedge Funds Are Warming Up To Alkermes Plc (ALKS)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Zacks
Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.
- Zacks
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
- Zacks
AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
- Zacks
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 6.4% in Session
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- Zacks
Epizyme Announces FDA Committee Review of Tazemetostat NDA
Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.
- Zacks
Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU
The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
- Zacks
Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 10.1%
Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
- Zacks
Global Blood (GBT) in Focus: Stock Moves 5.2% Higher
Global Blood (GBT) shares rose more than 5% in the last trading session, amid huge volumes.
- Zacks
BioDelivery's Belbuca Sales & Symproic Addition Encouraging
BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.
- Zacks
ChemoCentryx Up on Encouraging Rare Disease Candidate Data
ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.
- Zacks
Myovant (MYOV) Catches Eye: Stock Jumps 6.7%
Myovant (MYOV) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- Zacks
Intercept's (ICPT) NDA for NASH Drug Gets Priority Review
Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.
- Zacks
Alexion Gets Approval for Label Expansion of Soliris in Japan
Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.
- PR Newswire
Alkermes Completes Acquisition of Rodin Therapeutics
Alkermes plc (Nasdaq: ALKS) today announced that it has completed its previously announced acquisition of Rodin Therapeutics, Inc. (Rodin), a privately held biopharmaceutical company. This transaction builds on Alkermes' experience in central nervous system (CNS) diseases and expands Alkermes' CNS development efforts into a wide range of neurodegenerative disorders.
- Zacks
Biogen Ends Enrollment in Eye Disorder Study on Gene Therapy
Biogen (BIIB) completes enrollment in the global phase III STAR clinical study evaluating the gene therapy timrepigene emparvovec for the treatment of a rare, inherited retinal disorder.
